Clinical Trial Results: Safety and Efficacy of GSK Neisseria Gonorrhoeae GMMA (NgG) Investigational Vaccine When Administered to Healthy Adults 18 to 50 Years of Age [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 clinical trial assessing safety and efficacy of GSK NgG investigational vaccine for gonorrhea in healthy adults, completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Sexually Transmitted Diseases

Drugs mentioned

• NgG investigational vaccine (GSK Neisseria Gonorrhoeae GMMA (NgG) vaccine)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Sexually Transmitted Diseases | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2026-06-16